Lindpaintner Klaus
Roche Genetics, F. Hoffman-La Roche, Basel, Switzerland.
J Mol Med (Berl). 2003 Mar;81(3):141-53. doi: 10.1007/s00109-002-0416-5. Epub 2003 Mar 25.
Pharmacogenetics is today widely proclaimed to be about to revolutionize the face of medicine. In a more realistic assessment, the implementation of molecular genetics and biology will continue to provide us, as it has done already, with better ways to diagnose and treat illnesses, but it will do so at a stepwise and evolutionary pace, based on an improved understanding of the nature of disease, allowing more specific treatments, better risk prediction, and the implementation of preventive strategies. As such, future progress in biomedicine will travel the same well-trodden paths of improved differential diagnosis and risk prediction along which it has advanced in the past decades and centuries. Thus, while meaningful biomedical research today by and large depends on the use of the newly developed tools of genetics and genomics and the insights that we gain through them, it is unlikely fundamentally to change the direction of medical progress.
如今,药物遗传学被广泛宣称即将彻底改变医学面貌。更现实地评估,分子遗传学和生物学的应用将继续像过去那样,为我们提供更好的疾病诊断和治疗方法,但这将以循序渐进、逐步发展的速度进行,基于对疾病本质的更深入理解,实现更精准的治疗、更准确的风险预测以及预防策略的实施。因此,未来生物医学的进展将沿着过去几十年和几个世纪所走过的、在改进鉴别诊断和风险预测方面已有的成熟道路前行。所以,虽然当今有意义的生物医学研究大体上依赖于新开发的遗传学和基因组学工具以及从中获得的见解,但它不太可能从根本上改变医学进步的方向。